Changing Smokeless Tobacco Products. New Tobacco-Delivery Systems

Dorothy K. Hatsukami, Jon Owen Ebbert, Rachel M. Feuer, Irina Stepanov, Stephen S. Hecht

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Smokeless or noncombusted oral tobacco use as a substitute for cigarette smoking has been gaining greater interest and attention by the public health community and the tobacco industry. In order for the product to appeal to smokers, tobacco companies have been manufacturing new noncombusted oral tobacco (i.e., moist snuff) that is lower in moisture content and nitrosamine levels, packaged in small sachets and "spitless." While the primary motives of the major tobacco companies are to maintain or increase tobacco use, some members of the public health community perceive the use of noncombusted oral tobacco products as a harm reduction tool. Because cigarette smoking is associated with greater toxicant exposure compared to noncombusted oral tobacco, reduced mortality and morbidity are hypothesized to ensue, if cigarette smokers switched completely to these products. However, variability exists in levels of nicotine and toxicants and potential health consequences from use within and across countries. Therefore, promulgating noncombusted oral tobacco products as a safer alternative to smoking or as a substitute for smoking may engender more rather than less harm. To date, limited research is available on the effects of marketing noncombusted oral tobacco products to smokers, to support the use of these products as a harm reduction tool, and to determine the effects of varying levels of tobacco toxicants including nicotine on health. The need exists for manufacturing standards to lower toxicant levels of all noncombusted oral tobacco products, for the formulation of appropriate tobacco-product regulations and for the development of a strategic plan by the public health community to address this controversial topic.

Original languageEnglish (US)
JournalAmerican Journal of Preventive Medicine
Volume33
Issue number6 SUPPL.
DOIs
StatePublished - Dec 2007

Fingerprint

Smokeless Tobacco
Tobacco Products
Tobacco
Smoking
Harm Reduction
Public Health
Tobacco Use
Nicotine
Lobeline
Tobacco Industry
Nitrosamines
Health
Marketing
Morbidity
Mortality

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health

Cite this

Changing Smokeless Tobacco Products. New Tobacco-Delivery Systems. / Hatsukami, Dorothy K.; Ebbert, Jon Owen; Feuer, Rachel M.; Stepanov, Irina; Hecht, Stephen S.

In: American Journal of Preventive Medicine, Vol. 33, No. 6 SUPPL., 12.2007.

Research output: Contribution to journalArticle

Hatsukami, Dorothy K. ; Ebbert, Jon Owen ; Feuer, Rachel M. ; Stepanov, Irina ; Hecht, Stephen S. / Changing Smokeless Tobacco Products. New Tobacco-Delivery Systems. In: American Journal of Preventive Medicine. 2007 ; Vol. 33, No. 6 SUPPL.
@article{d01dd2d4c46e4ca4b3e5eb947f463f49,
title = "Changing Smokeless Tobacco Products. New Tobacco-Delivery Systems",
abstract = "Smokeless or noncombusted oral tobacco use as a substitute for cigarette smoking has been gaining greater interest and attention by the public health community and the tobacco industry. In order for the product to appeal to smokers, tobacco companies have been manufacturing new noncombusted oral tobacco (i.e., moist snuff) that is lower in moisture content and nitrosamine levels, packaged in small sachets and {"}spitless.{"} While the primary motives of the major tobacco companies are to maintain or increase tobacco use, some members of the public health community perceive the use of noncombusted oral tobacco products as a harm reduction tool. Because cigarette smoking is associated with greater toxicant exposure compared to noncombusted oral tobacco, reduced mortality and morbidity are hypothesized to ensue, if cigarette smokers switched completely to these products. However, variability exists in levels of nicotine and toxicants and potential health consequences from use within and across countries. Therefore, promulgating noncombusted oral tobacco products as a safer alternative to smoking or as a substitute for smoking may engender more rather than less harm. To date, limited research is available on the effects of marketing noncombusted oral tobacco products to smokers, to support the use of these products as a harm reduction tool, and to determine the effects of varying levels of tobacco toxicants including nicotine on health. The need exists for manufacturing standards to lower toxicant levels of all noncombusted oral tobacco products, for the formulation of appropriate tobacco-product regulations and for the development of a strategic plan by the public health community to address this controversial topic.",
author = "Hatsukami, {Dorothy K.} and Ebbert, {Jon Owen} and Feuer, {Rachel M.} and Irina Stepanov and Hecht, {Stephen S.}",
year = "2007",
month = "12",
doi = "10.1016/j.amepre.2007.09.005",
language = "English (US)",
volume = "33",
journal = "American Journal of Preventive Medicine",
issn = "0749-3797",
publisher = "Elsevier Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Changing Smokeless Tobacco Products. New Tobacco-Delivery Systems

AU - Hatsukami, Dorothy K.

AU - Ebbert, Jon Owen

AU - Feuer, Rachel M.

AU - Stepanov, Irina

AU - Hecht, Stephen S.

PY - 2007/12

Y1 - 2007/12

N2 - Smokeless or noncombusted oral tobacco use as a substitute for cigarette smoking has been gaining greater interest and attention by the public health community and the tobacco industry. In order for the product to appeal to smokers, tobacco companies have been manufacturing new noncombusted oral tobacco (i.e., moist snuff) that is lower in moisture content and nitrosamine levels, packaged in small sachets and "spitless." While the primary motives of the major tobacco companies are to maintain or increase tobacco use, some members of the public health community perceive the use of noncombusted oral tobacco products as a harm reduction tool. Because cigarette smoking is associated with greater toxicant exposure compared to noncombusted oral tobacco, reduced mortality and morbidity are hypothesized to ensue, if cigarette smokers switched completely to these products. However, variability exists in levels of nicotine and toxicants and potential health consequences from use within and across countries. Therefore, promulgating noncombusted oral tobacco products as a safer alternative to smoking or as a substitute for smoking may engender more rather than less harm. To date, limited research is available on the effects of marketing noncombusted oral tobacco products to smokers, to support the use of these products as a harm reduction tool, and to determine the effects of varying levels of tobacco toxicants including nicotine on health. The need exists for manufacturing standards to lower toxicant levels of all noncombusted oral tobacco products, for the formulation of appropriate tobacco-product regulations and for the development of a strategic plan by the public health community to address this controversial topic.

AB - Smokeless or noncombusted oral tobacco use as a substitute for cigarette smoking has been gaining greater interest and attention by the public health community and the tobacco industry. In order for the product to appeal to smokers, tobacco companies have been manufacturing new noncombusted oral tobacco (i.e., moist snuff) that is lower in moisture content and nitrosamine levels, packaged in small sachets and "spitless." While the primary motives of the major tobacco companies are to maintain or increase tobacco use, some members of the public health community perceive the use of noncombusted oral tobacco products as a harm reduction tool. Because cigarette smoking is associated with greater toxicant exposure compared to noncombusted oral tobacco, reduced mortality and morbidity are hypothesized to ensue, if cigarette smokers switched completely to these products. However, variability exists in levels of nicotine and toxicants and potential health consequences from use within and across countries. Therefore, promulgating noncombusted oral tobacco products as a safer alternative to smoking or as a substitute for smoking may engender more rather than less harm. To date, limited research is available on the effects of marketing noncombusted oral tobacco products to smokers, to support the use of these products as a harm reduction tool, and to determine the effects of varying levels of tobacco toxicants including nicotine on health. The need exists for manufacturing standards to lower toxicant levels of all noncombusted oral tobacco products, for the formulation of appropriate tobacco-product regulations and for the development of a strategic plan by the public health community to address this controversial topic.

UR - http://www.scopus.com/inward/record.url?scp=36049024100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049024100&partnerID=8YFLogxK

U2 - 10.1016/j.amepre.2007.09.005

DO - 10.1016/j.amepre.2007.09.005

M3 - Article

VL - 33

JO - American Journal of Preventive Medicine

JF - American Journal of Preventive Medicine

SN - 0749-3797

IS - 6 SUPPL.

ER -